55
Studies Synthesised
1991 – 2025
−3.5d
ICU LOS Reduction
Daily sedation interruption
−2.4d
MV Duration Reduction
DSI vs. continuous sedation
+41%
Prolonged Hosp. Risk
ICU delirium (HR 1.41)
Evidence Overview

The Sedation–LOS Relationship

Three decades of evidence consistently show that sedation strategy is one of the strongest modifiable determinants of ICU length of stay and mechanical ventilation duration.

Mechanical Ventilation Duration

Hours of MV by sedation approach (mean ± SD)

Source: Kollef et al. 1998; Kress et al. 2000; Strom et al. 2010

ICU Length of Stay

Days in ICU by sedation approach (mean)

Source: Kollef et al. 1998; Kress et al. 2000; Protocolized Sedation Meta-analysis 2015

Prevalence of Sub-Optimal Sedation in ICUs

Over-sedation and under-sedation rates identified across international surveys (Jackson et al. 2009 systematic review)

Over-sedation (too deep)68%
Under-sedation (too light)14%
Optimal sedation achieved18%
ICUs using formal sedation protocol40%
Sedation Strategies

Strategies & Their Impact on LOS

Click each strategy to explore the evidence, key trials, and quantitative outcomes.

Landmark Evidence

Daily Sedation Interruption (DSI)

DSI involves the daily cessation of continuous sedative infusions until patients are awake and responsive, followed by re-titration to the minimum effective dose. The landmark Kress et al. (2000) RCT in the New England Journal of Medicine established DSI as a major clinical advance, demonstrating significant reductions in both MV duration and ICU LOS.

−2.4 days
MV duration reduction
(4.9 vs 7.3 days, p=0.004)
−3.5 days
ICU LOS reduction
(6.4 vs 9.9 days, p=0.02)

Subsequent evidence showed DSI combined with spontaneous breathing trials (SAT+SBT bundle) further reduced MV duration and ICU LOS. However, the 2012 SLEAP trial (Mehta et al.) found no additional benefit of DSI over protocolized sedation alone, suggesting that light sedation targets within protocols may be equally effective.

DSI vs. Continuous Sedation — Key Trial Outcomes

→Kress 2000 (NEJM): 128 ICU patients; DSI group had 33% fewer diagnostic tests (p=0.02)
→SLEAP 2012 (JAMA): DSI + protocol vs protocol alone — no significant LOS difference
→2019 Literature Review: DSI consistently reduces MV duration when added to non-protocolised care
Pharmacology

Sedation Agents Compared

Agent selection significantly influences clinical outcomes. The shift from benzodiazepines to propofol and dexmedetomidine has been associated with shorter MV duration and improved weaning.

Time to Extubation by Agent

Hours from sedation to extubation (key RCT data)

Sources: MIDEX/PRODEX 2012; SEDCOM 2009; REMICAM 2011

Propofol
Short-acting

Rapid onset/offset; favoured for short-term sedation. MIDEX trial showed dexmedetomidine achieved extubation 24h faster than propofol (69 vs 93h, p=0.04). Propofol shortage studies showed switching to midazolam increased MV duration by 1.3 days.

Midazolam (Benzodiazepine)
Long-acting

Historically dominant agent; accumulates with prolonged use. Associated with longer MV duration and ICU LOS compared to propofol and dexmedetomidine. Benzodiazepine use independently associated with delirium development (OR 3.0).

Dexmedetomidine
α₂-agonist

Unique mechanism: sedation without respiratory depression. SEDCOM trial: dexmedetomidine vs midazolam reduced time to extubation by 46h (101 vs 147h, p=0.01) and delirium prevalence (54% vs 76.6%, p<0.001).

Remifentanil
Opioid analgesic

Ultra-short-acting opioid for analgo-sedation. Esterase-metabolised; predictable offset regardless of infusion duration. Enables faster weaning; cost offset by shorter MV duration in economic analyses.

International Agent Preferences Over Time

Evolution of sedation agent use across European, Australian, and North American ICUs based on survey data (1991–2012)

Sources: Soliman 1991; Murdoch 2001 European Survey; Egerod 2006 German Survey; Mehta 2007 Ontario Survey; O'Connor 2009 ANZ Survey

Complications

Delirium, Agitation & LOS

ICU delirium is an independent predictor of prolonged hospitalisation, increased mortality, and long-term cognitive impairment. Sedation depth directly influences delirium incidence.

HR 1.41
Risk of Prolonged Hospitalisation
Delirious ICU patients had 41% greater risk of remaining hospitalised (95% CI 1.05–1.89, p=0.023)
Ouimet et al. 2007
+11 days
Additional Hospital LOS
Delirious patients spent an average of 11 more days in hospital compared to non-delirious patients
Ouimet et al. 2007
−22%
Delirium Reduction
Dexmedetomidine vs midazolam reduced delirium prevalence from 76.6% to 54% (p<0.001)
SEDCOM Trial 2009

Delirium Detection Tools

Sensitivity and specificity of validated ICU delirium screening tools

Source: Comparison of CAM-ICU and ICDSC, 2012

Risk Factors for ICU Delirium

Benzodiazepines
OR 3.0
Deep sedation
High
Immobility
Mod
Age >65
Mod
Dexmedetomidine
Low
Light sedation
Low

Risk level for delirium development (high = increased risk; low = protective)

Monitoring

Sedation Assessment Tools

Reliable sedation monitoring is a prerequisite for targeted sedation. The evolution from subjective assessment to validated scales has been critical in enabling protocol-directed care.

Validated 2003

RASS

Richmond Agitation-Sedation Scale

10-point scale (−5 to +4). Validated by Ely et al. (2003, JAMA) with excellent inter-rater reliability (κ=0.91). Enables targeted sedation to RASS −1 to 0, the current gold standard. Cited 1,405+ times.

κ=0.91 reliability−5 to +4
Validated 1999

SAS

Sedation-Agitation Scale

7-point scale. Riker et al. (1999) demonstrated good inter-rater reliability. One of the first validated ICU sedation scales. Widely used before RASS became the dominant tool.

7-point scaleNurse-administered
Validated 1999

Brussels Scale

Brussels Sedation Scale

Simple 5-point scale. De Lemos et al. (1999) demonstrated that use of the Brussels scale avoided excessive sedation in mechanically ventilated patients. Practical for bedside nursing use.

5-point scaleSimple
Objective

BIS / Entropy

Bispectral Index / Spectral Entropy

EEG-derived objective measures. Assessed in 2008 study for sedation monitoring in ICU. Useful for non-communicative patients; limited by movement artefact and cost. Not recommended as routine replacement for clinical scales.

EEG-basedObjective
Delirium

CAM-ICU

Confusion Assessment Method for ICU

Validated delirium screening tool adapted for non-verbal ICU patients. 2012 comparison with ICDSC showed high sensitivity (80%) and specificity (96%). Recommended in SCCM 2013 PAD guidelines.

Sens 80%Spec 96%
Delirium

ICDSC

Intensive Care Delirium Screening Checklist

8-item checklist for ICU delirium screening over 24-hour periods. More sensitive than CAM-ICU for subsyndromal delirium (sensitivity 99%). Useful for capturing fluctuating delirium missed by point-in-time assessments.

Sens 99%8-item
Historical Evolution

Three Decades of Evidence

Key milestones in the evolution of ICU sedation practice from 1991 to 2025.

1991Survey

Deep Sedation Era Documented

Soliman et al. national survey revealed widespread use of deep sedation with morphine and diazepam in mechanically ventilated patients, with no standardised assessment. Established baseline of current practice.

1998Landmark

Continuous IV Sedation Linked to Prolonged MV

Kollef et al. (Chest) demonstrated continuous IV sedation independently associated with prolonged MV (185±190h vs 55.6±75.6h, p<0.001) and ICU LOS (13.5±33.7d vs 4.8±4.1d, p<0.001).

1999Tool

Brussels Scale & SAS Validated

First validated clinical sedation scales introduced. De Lemos et al. showed Brussels scale avoided excessive sedation. Riker et al. validated the SAS. Paved the way for targeted sedation protocols.

2000RCT · NEJM

Kress DSI Trial — Paradigm Shift

Kress et al. (NEJM) demonstrated daily sedation interruption reduced MV duration by 2.4 days (p=0.004) and ICU LOS by 3.5 days (p=0.02). Transformed global ICU sedation practice.

2002Guidelines

SCCM First Sedation Guidelines

Jacobi et al. published first SCCM clinical practice guidelines for sustained use of sedatives and analgesics in critically ill adults. Recommended use of validated sedation scales and lightest effective sedation.

2003Tool · JAMA

RASS Validated (Ely et al., JAMA)

Richmond Agitation-Sedation Scale validated with excellent inter-rater reliability (κ=0.91). Became the dominant sedation monitoring tool in ICUs worldwide. Now cited over 1,400 times.

2009–2010RCTs

SEDCOM + No-Sedation Trial

SEDCOM (2009): dexmedetomidine reduced delirium vs midazolam (54% vs 76.6%). Strom et al. (2010, Lancet): no-sedation protocol reduced MV by 4 days and ICU LOS by 9 days versus sedation+DSI.

2013Guidelines

SCCM PAD Guidelines — Light Sedation Target

Barr et al. published landmark SCCM PAD guidelines recommending RASS −1 to 0 as target, analgo-first approach, routine delirium monitoring with CAM-ICU/ICDSC, and early mobilisation as standard of care.

2015Meta-Analysis

Protocolized Sedation Meta-Analysis

Systematic review confirmed protocol-directed sedation reduced ICU LOS by 1.73 days and hospital LOS by 3.55 days. Cochrane review (Aitken et al.) supported protocol-directed sedation for reducing MV duration.

2020–2023Innovation

NONSEDA Trial + Telehealth SAT/SBT

NONSEDA (2020): light sedation non-inferior to no sedation on 90-day mortality. Telehealth-enabled real-time audit of SAT/SBT compliance (2023) demonstrated feasibility of remote protocol monitoring to improve adherence.

2025Emerging

AI in Critical Care Sedation Management

AI-driven decision support systems emerging for real-time sedation titration. Machine learning models can predict optimal sedation targets and flag delirium risk. Ethical frameworks and clinical validation remain active areas of development.

Special Populations

Beyond the General ICU Adult

Sedation requirements and optimal strategies differ significantly across patient subgroups.

Paediatric ICU

ANZ paediatric survey (2005) revealed significant variation in sedation practices. 2016 RCT of DSI in critically ill children showed no significant LOS benefit, contrasting with adult evidence. Age-specific validated tools essential.

Tracheotomy Patients

Tracheotomy significantly reduced sedative requirements and improved sedation levels (2005). Patients with tracheotomy had significantly lower sedation scores and required less midazolam, enabling earlier mobilisation.

NIV Patients

RCT comparing dexmedetomidine vs midazolam for sedation during NIV (2010) showed dexmedetomidine maintained respiratory drive better, with lower rates of NIV failure and intubation. Sedation during NIV requires careful agent selection.

Trauma ICU

Protocol-driven ventilator management in trauma ICU (2002) reduced MV duration. Analgesia-delirium-sedation protocol in trauma patients (Robinson 2008) reduced ventilator days and hospital LOS significantly.

Meta-Analytic Visualisation

Forest Plot: ICU LOS Reduction

Mean difference in ICU length of stay (days) compared with control, grouped by sedation strategy. Negative values favour the intervention. Square size is proportional to study weight; diamonds represent subgroup and overall pooled estimates.

−2.0d
DSI Subtotal
[−4.0, −0.1]
−1.6d
Protocol-Directed
[−3.2, −0.0]
−6.0d
No-Sedation
[−9.7, −2.3]
−1.5d
Overall Pooled
[−1.9, −1.1]
Forest plot showing ICU length of stay reduction by sedation strategy across 13 trials

Largest Effect

No-Sedation / Light Sedation strategies show the greatest ICU LOS reduction (subtotal −6.0 days), driven primarily by Strom et al. 2010 (−9.0 days, Lancet).

Most Consistent

Daily Sedation Interruption demonstrates consistent benefit across all three included trials (Kress 2000, Girard 2008, Mehta 2012), with a subtotal of −2.0 days.

Overall Evidence

The overall pooled estimate of −1.5 days (95% CI −1.9 to −1.1) across 13 trials confirms a statistically significant ICU LOS reduction for active sedation management strategies versus standard care.

MD = Mean Difference; CI = Confidence Interval. Pooled estimates are descriptive weighted means; formal meta-analysis recommended for inferential conclusions. Sources: 55-paper Mendeley evidence base (1991–2025).

Evidence-Based Practice

Clinical Recommendations

Based on synthesis of 55 studies and SCCM PAD 2013 guidelines, the following recommendations are supported by the strongest evidence.

1

Target Light Sedation (RASS −1 to 0)

Multiple RCTs and meta-analyses demonstrate light sedation reduces MV duration, ICU LOS, and delirium. RASS −1 to 0 is the recommended target per SCCM PAD 2013 guidelines.

Strong Evidence (Level A)
2

Implement Nurse-Led Sedation Protocols

Protocol-directed sedation reduces ICU LOS by 1.73 days and hospital LOS by 3.55 days. Nursing-led protocols with defined sedation targets are feasible and effective across diverse ICU settings.

Strong Evidence (Level A)
3

Adopt Analgo-First Approach

Prioritise adequate analgesia before adding sedatives. Remifentanil-based analgo-sedation enables faster weaning. Reduces total sedative exposure and associated complications including delirium.

Moderate Evidence (Level B)
4

Monitor Sedation with Validated Scales

Use RASS (or SAS) for routine sedation monitoring. Assess delirium with CAM-ICU or ICDSC at least once per shift. Objective monitoring enables targeted titration and early intervention.

Moderate Evidence (Level B)
5

Prefer Non-Benzodiazepine Agents

Dexmedetomidine and propofol preferred over benzodiazepines for ICU sedation. Benzodiazepines independently associated with delirium (OR 3.0) and prolonged MV duration.

Moderate Evidence (Level B)
6

Implement SAT/SBT Bundle Daily

Coordinated spontaneous awakening trials (SAT) paired with spontaneous breathing trials (SBT) reduce MV duration and ICU LOS. Telehealth-enabled audit improves protocol compliance in real-world settings.

Moderate Evidence (Level B)

LOS Impact Summary Across Strategies

Days saved in ICU LOS compared to standard/continuous sedation (from key trials and meta-analyses)

Full Research Report Available

Download the Complete Branded PDF Report

The full 40-page evidence synthesis — covering all 55 studies, 11 sections, executive summary, and 63 references — formatted with CCP branding for clinical use and sharing.

40 Pages · A4 Format
55 Studies Synthesised
63 References · 1991–2025
CCP Branded · Print-Ready
Download Full PDF Report (426 KB)

Free to download · No sign-up required · The Critical Care Practitioner